20 June 2018 | News
This $20 million 6,000 square meter facility will be operational in 2019 and provide integrated solutions from concept to commercialization for biologics conjugates including Antibody-Drug Conjugates (ADCs) and other protein conjugates
WuXi Biologics , a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today that it has started the construction of a state-of-the-art integrated biologics conjugate solution center in Wuxi city, China.
This $20 million 6,000 square meter facility will be operational in 2019 and provide integrated solutions from concept to commercialization for biologics conjugates including Antibody-Drug Conjugates (ADCs) and other protein conjugates.
ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic drug and are becoming emerging treatments of targeted tumor therapy. WuXi Biologics plans to build this site into a world-class ADC R&D and manufacturing platform which will meet US, EU and Chinese cGMP standards.
"I am very excited about this new investment in ADCs," Dr. Chris Chen, CEO of WuXi Biologics said. "In collaboration with chemistry division of WuXi AppTec Group, WuXi Biologics is one of the few global companies that can provide the one-stop service to global partners for antibodies, small molecule payloads, ADCs drug substance and drug products. Our vision is to empower any global partners to develop any ADC to benefit patients."
WuXi is on an expansion spree. The company recently announced its investment of $60 million to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility (MFG11).
The company is also building an integrated biologics development, clinical and commercial manufacturing center in the city of Shijiazhuang, capital of Hebei province in northern China.
The new state-of-the-art biologics center will include process development labs, clinical manufacturing facility (MFG9) with 5,000 L bioreactor capacity and commercial manufacturing facility (MFG8) with 48,000 L bioreactor capacity which will be built to meet cGMP standards of the United States, the European Union, and China. Besides serving global clients, the new integrated center will also support Marketing Authorization Holder (MAH) system in China and address urgent needs of Chinese partners. Initial phase of the center will be operational in 2020.